RxDoctor Payments Data

Leslie Rickey, MD

Urology · New Haven, CTNPI 1396930079

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $14,850 of the $17,091 with a category attached, or 86.9%. 8 manufacturers reported payments, led by GSK at 54.6% of the total. 2025 is the largest year on record at $9,755, 2.1 times the $4,566 reported in 2019.

$17,091in general payments, 2019–2025

Across 29 payments — averaging $589.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$9K
  • Urocure LLC$6K
  • Boston Scientific$730
  • Renovia Inc$600
  • AbbVie$412
  • Medtronic$339
  • plus $75 from 2 others

What the payments were for

  • Consulting fees$14,85087%
  • Travel & lodging$7474%
  • Food & beverage$1,4949%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK5$9,330
Urocure LLC7$5,605
Boston Scientific6$730
Renovia Inc2$600
AbbVie(2 entities)3$412
Medtronic4$339
Applied Medical Resources Corporation1$53
Baxter Healthcare1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,091 in reported general payments places this provider in the 85th percentile of 156 urology providers in Connecticut.

See all urology providers in Connecticut

Medicare billing

Part B allowed, 2024
$62,577
Medicare patients
211
Services billed
462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron27$16,710
MyrbetriqMirabegron12$6,267
Estradiol51$2,594

Paid to pharmacies, not to this prescriber.

Other urology in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →